RedHill Biopharma announced partnerships to expand manufacturing for COVID-19 therapeutic candidate opaganib

, , , ,

On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to ramp-up manufacturing of opaganib, then in swiftly progressing global Phase 2/3 and U.S. Phase 2 studies for severe COVID-19 pneumonia, to support potential emergency use applications and subsequent demand.

Opaganib is a first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with demonstrated dual anti-inflammatory and antiviral activity that targets a host cell component, potentially minimizing the likelihood of viral resistance.

The late-stage development program for opaganib in patients with severe COVID-19 pneumonia includes: The U.S. Phase 2 study (NCT04414618), ongoing in eight clinical trial sites, is approaching completion of enrollment, and recently passed a second independent committee review, with data expected to follow before the end of this year; and the global Phase 2/3 study (NCT04467840), which is enrolling rapidly across 15 study sites and is on track to enroll up to 270 patients by the end of the year. Both studies are randomized, double-blind, parallel-arm, placebo-controlled trials with opaganib in patients with severe COVID-19 pneumonia requiring hospitalization and treatment with supplemental oxygen.

Opaganib demonstrated potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19, completely inhibiting viral replication in an in vitro model of human lung bronchial tissue. The Company is in discussions with U.S. government agencies around potential funding to support the rapid advancement of opaganib toward potential emergency use applications and manufacturing scale-up.

Opaganib, a new chemical entity, is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with demonstrated dual anti-inflammatory and antiviral activity that targets a host cell component, potentially minimizing the likelihood of viral resistance. Opaganib has also shown anticancer activity and has the potential to target multiple oncology, viral, inflammatory, and gastrointestinal indications.

Tags:


Source: RedHill Biopharma
Credit:

bioinnovatise accelerates scientific discovery by providing fast, reliable, and high-quality CDMO services for plasmid DNA and viral vector-based research.